Today: 7 February 2026
Subscribe
Browse Category

NYSE:ONTO News 11 December 2025

Onto Innovation (ONTO) Stock on December 11, 2025: Latest Price, Q3 Earnings, Semilab Deal and 2026 Forecasts

Onto Innovation (ONTO) Stock on December 11, 2025: Latest Price, Q3 Earnings, Semilab Deal and 2026 Forecasts

December 11, 2025 – Markets / Semiconductors / Stock Analysis Onto Innovation Inc. (NYSE: ONTO), a mid‑cap supplier of semiconductor process control and inspection tools, is back in focus after a sharp intraday pullback, fresh short‑interest data and the recent closing of a $495 million acquisition that reshapes its growth outlook for 2026. Onto Innovation+1 Below is a detailed look at today’s trading, the latest fundamentals, new strategic moves and what Wall Street expects from ONTO stock over the next 12 months. Onto Innovation stock price today Around early afternoon U.S. trading on Thursday, December 11, 2025, Onto Innovation shares
11 December 2025
····

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop